^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bavunalimab (XmAb22841)

    i
    Other names: XmAb22841, XmAb 22841, XmAb841
    Associations

    News

    Trials
    Company:
    Xencor
    Drug class:
    CTLA4 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    8ms
    XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=46 --> 6
    Enrollment closed • Phase classification • Enrollment change • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • LAG3 (Lymphocyte Activating 3)
    |
    bavunalimab (XmAb22841) • izuralimab (XmAb23104)
    1year
    Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease (SITC 2023)
    1. At the time of this abstract submission, Cohort 1 of dose escalation has begun with the first few patients still within the DLT observation window.
    P1/2 data • Checkpoint inhibition • Metastases
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator)
    |
    bavunalimab (XmAb22841) • izuralimab (XmAb23104)
    over1year
    Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease. (ASCO 2023)
    At the time of this abstract submission, Cohort 1 of dose escalation has begun with the first few patients still within the DLT observation window. Clinical trial information: NCT05695898.
    P1/2 data • Checkpoint inhibition • Metastases
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator)
    |
    bavunalimab (XmAb22841) • izuralimab (XmAb23104)
    over1year
    DUET-4: A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=78, Completed, Xencor, Inc. | Active, not recruiting --> Completed | N=242 --> 78 | Trial completion date: Nov 2025 --> Feb 2023 | Trial primary completion date: Jun 2024 --> Feb 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • bavunalimab (XmAb22841)
    over1year
    XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy (clinicaltrials.gov)
    P1/2, N=46, Recruiting, University of California, San Francisco | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • LAG3 (Lymphocyte Activating 3)
    |
    bavunalimab (XmAb22841) • izuralimab (XmAb23104)
    almost2years
    XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy (clinicaltrials.gov)
    P1/2, N=46, Not yet recruiting, University of California, San Francisco
    New P1/2 trial • Checkpoint inhibition • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • LAG3 (Lymphocyte Activating 3)
    |
    bavunalimab (XmAb22841) • izuralimab (XmAb23104)
    over2years
    DUET-4: A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=242, Active, not recruiting, Xencor, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • bavunalimab (XmAb22841)
    over3years
    DUET-4: A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=242, Recruiting, Xencor, Inc. | Trial completion date: Mar 2027 --> Nov 2025 | Trial primary completion date: Sep 2026 --> Jun 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • bavunalimab (XmAb22841)